In AbbVie Deutschland Gmbh v. Janssen Biotech, Inc., the Federal Circuit affirmed the district court decision that found AbbVie’s patents directed to anti-IL-12 antibodies invalid for lack of adequate written description. As between the parties, this decision leaves Centocor free to market its Stelara® product for the treatment of psoriasis. More generally, this decision emphasizes the … Continue reading this entry
Tags: AbbVie, Antibodies, Centocor, Genus, Species
On Thursday, March 31, at 3:00 PM Eastern Time (12:00 PM Pacific Time), I will be speaking during a Law Seminars International TeleBriefing titled “Centocor Ortho Biotech, Inc. v. Abbott Laboratories,” discussing the impact of the Federal Circuit’s recent decision. The panel consists of: Donald L. Zuhn, Ph.D, Esq., McDonnell Boehnen Hulbert & Berghoff LLP, … Continue reading this entry
Tags: 112, Abbott, Antibodies, Centocor, Humira, Written Description, Written Description Guidelines
As I wrote last week, the Federal Circuit held in Centocor Ortho Biotech, Inc. v. Abbott Laboratories, that the human antibody claims that Centocor had asserted against Abbott’s Humira® product are invalid for failing to satisfy the written description requirement of 35 USC § 112. The holding is getting lots of attention because it will negate a … Continue reading this entry
Tags: 112, Abbott, Antibodies, Centocor, Constructive Possession, Humira, Written Description
Yesterday, in Centocor Ortho Biotech, Inc. v. Abbott Laboratories, the Federal Circuit held that the human antibody claims that Centocor had asserted against Abbott’s Humira® product (claims 2, 3, 14 and 15 of U.S. 7,070,775) are invalid for failing to satisfy the written description requirement of 35 USC § 112. (This decision will negate a $1.67 billion damages … Continue reading this entry
Tags: 112, Abbott, Antibodies, Centocor, Humira, Written Description, Written Description Guidelines